• Politics
  • Diversity, equity and inclusion
  • Financial Decision Making
  • Telehealth
  • Patient Experience
  • Leadership
  • Point of Care Tools
  • Product Solutions
  • Management
  • Technology
  • Healthcare Transformation
  • Data + Technology
  • Safer Hospitals
  • Business
  • Providers in Practice
  • Mergers and Acquisitions
  • AI & Data Analytics
  • Cybersecurity
  • Interoperability & EHRs
  • Medical Devices
  • Pop Health Tech
  • Precision Medicine
  • Virtual Care
  • Health equity

410 Medical Closes $8M Funding Round for Fluid Delivery Medical Device


The tech is designed to help docs efficiently deliver fluids to critically ill patients.


Photo/Thumb have been modified. Courtesy of teerawit - stock.adobe.com.

410 Medical today announced the closing of an $8 million funding round for its critical care technology, LifeFlow.

LifeFlow is designed to help clinicians effectively and efficiently deliver fluids to critically ill patients. The medical device delivers fluids up to 10 times faster than traditional methods, said Kyle Chenet, MBA, CEO of 410 Medical. The company touts that LifeFlow can deliver 500 mL in less than two minutes.

“In the emergency department, being able to rapidly infuse fluids is of extreme importance,” said Chris Brock, M.D., an emergency medicine physician at WakeMed Health & Hospitals.

The U.S. Food and Drug Administration cleared the medical device in 2016.

“This new funding will be instrumental in expanding commercialization of LifeFlow in hospital and pre-hospital environments nationwide, ensuring that more patients receive time-sensitive fluid resuscitation,” Chenet said.

Healthcare systems throughout the U.S., including Cincinnati Children’s Hospital Medical Center, Children’s Hospital Colorado and WakeMed Health & Hospitals, have adopted LifeFlow.

Rapid resuscitation can be used for patients who are septic or trauma patients who are bleeding extensively and are hypotensive, said Sarah Williford, R.N., a nurse in the emergency department of WakeMed Health & Hospitals.

But providers fail to achieve fluid delivery guidelines based on existing methods.

“Most of the techniques that we currently use are either very complex, expensive or too slow and they end up resulting in ineffective treatment,” said Mark Piehl, M.D., a pediatric intensive care physician at WakeMed.

Early and rapid delivery of fluid can be a life-saving therapy.

Hatteras Venture Partners led the funding, with additional participation from OSF Healthcare and existing investor Sovereign’s Capital.

Get the best insights in digital health directly to your inbox.


FDA Clears Wearable to Prevent Patients at Risk of Venous Thromboembolism

Advanced Surgical Robotics Beyond the Surgical Suite

FDA Clears ProTom's Proton Therapy System

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.